Drugs / ICON-1
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02771340 | May 2016 → Sep 2017 | choroid neoplasm, uveal melanoma | Iconic Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03452527 | Mar 2018 → Apr 2019 | choroidal neovascularization, wet macular degeneration | Iconic Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICON-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03452527 ↗ |
| Route | Intravitreal | “Intravitreal injection of ICON-1” NCT02771340 ↗ |